Senores Pharmaceuticals FY26 Revenue at ₹663 Crore, Up 62%; PAT Grows 108% to ₹122 Crore
Senores Pharmaceuticals reported FY26 revenue of ₹663 crore, a 62% increase, and PAT of ₹122 crore, up 108%. The company projects FY27 revenue growth of 30-40% and PAT growth of 50-60%. In Q4FY26, they acquired 75% stake in Apnar Pharma and also acquired Zoraya Pharmaceuticals in Q3FY26. A strategic joint venture called Amerisyn was formed in April.
The substantial financial growth, strategic acquisitions, and positive future guidance suggest a high impact on the company's performance and market position.
The announcement highlights significant revenue and profit growth, along with strategic acquisitions and joint ventures, indicating a positive outlook for the company.
Senores Pharmaceuticals Limited announced the transcript of the Earnings Conference Call for Q4FY26, held on May 14, 2026. The company achieved approximately 62% revenue growth and 108% PAT growth in FY26 over FY25, with total revenue reaching ₹663 crore and a profit of ₹122 crore. For FY27, the company's initial outlook indicates revenue growth of approximately 30% to 40% and PAT growth of about 50% to 60%. Revenue from the regulated market registered a robust growth of 83% Y-o-Y in FY26. As of March 2026, the company had a portfolio of 51 approved ANDAs.
The company acquired a 75% stake in Apnar Pharma in Q4FY26, with the remaining 25% expected by the end of the year. In Q3FY26, Zoraya Pharmaceuticals was acquired as a step-down subsidiary. In April, a strategic agreement was entered into for a joint venture called Amerisyn. Emerging market revenue grew by 20% in FY26, with improved EBITDA margins. The branded generic business segment in India saw revenue for FY26 reach approximately ₹40 crore, growing nearly five times from FY25.
Mr. Swapnil Shah, Promoter and Managing Director, stated that the company delivered a robust performance across segments during the quarter and throughout FY26, guided by well-defined strategies and strong execution capabilities. Mr. Deval Shah, Chief Financial Officer, mentioned that the consolidated income for FY26 stood at ₹664 crore, reflecting a strong growth of 62% Y-o-Y.
What to do with a filing like this
Senores Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Senores Pharmaceuticals Limited. Read the original for the full detail.